Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 1/2003

01-02-2003

A Phase II Study of Rebeccamycin Analog NSC 655649 in Patients with Metastatic Colorectal Cancer

Authors: Sanjay Goel, Scott Wadler, Anthony Hoffman, Fabio Volterra, Cheryl Baker, Elliot Nazario, Percy Ivy, Alyson Silverman, Sridhar Mani

Published in: Investigational New Drugs | Issue 1/2003

Login to get access
Metadata
Title
A Phase II Study of Rebeccamycin Analog NSC 655649 in Patients with Metastatic Colorectal Cancer
Authors
Sanjay Goel
Scott Wadler
Anthony Hoffman
Fabio Volterra
Cheryl Baker
Elliot Nazario
Percy Ivy
Alyson Silverman
Sridhar Mani
Publication date
01-02-2003
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 1/2003
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1023/A:1022980613420

Other articles of this Issue 1/2003

Investigational New Drugs 1/2003 Go to the issue

OriginalPaper

Phase II Study of Single Agent Paclitaxel in Adult Patients with Relapsed Acute Lymphocytic Leukemia

OriginalPaper

An Overview on the Antileukemic Potential of D-homo-aza- and Respective 17β-Acetamido-Steroidal Alkylating Esters

OriginalPaper

Current Approaches to Novel Therapeutics in Pancreatic Cancer

OriginalPaper

A Phase I and Pharmacologic Study of Pyrazoloacridine and Cisplatin in Patients with Advanced Cancer

OriginalPaper

Phase I and Pharmacologic Study of the Human DNA Methyltransferase Antisense Oligodeoxynucleotide MG98 given as a 21-day Continuous Infusion Every 4 Weeks

OriginalPaper

Reversal of Tumor-induced Immunosuppression by TGF-β Inhibitors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits